Billing Code 4410-09-M

DEPARTMENT OF JUSTICE DRUG ENFORCEMENT ADMINISTRATION MANUFACTURER OF CONTROLLED SUBSTANCES NOTICE OF APPLICATION

Pursuant to § 1301.33(a), Title 21 of the Code of Federal Regulations (CFR), this is notice that on November 7, 2011, Mallinckrodt, LLC, 3600 North Second Street, St. Louis, Missouri 63147, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances:

| Drug | Schedule |
|------------------------------|----------|
| | |
| Tetrahydrocannabinols (7370) | I |
| Codeine-N-oxide (9053) | I |
| Dihydromorphine (9145) | I |
| Difenoxin (9168) | I |
| Morphine-N-oxide (9307) | I |
| Normorphine (9313) | I |
| Norlevorphanol (9634) | I |
| Amphetamine (1100) | II |

Drug Schedule

| Methamphetamine (1105) | II |
|------------------------------------|----|
| Methylphenidate (1724) | II |
| Nabilone (7379) | II |
| 4-Anilino-N-phenethyl-4-piperidine | |
| (8333) | II |
| Codeine (9050) | II |
| Dihydrocodeine (9120) | II |
| Oxycodone (9143) | II |
| Hydromorphone (9150) | II |
| Diphenoxylate (9170) | II |
| Ecgonine (9180) | II |
| Hydrocodone (9193) | II |
| Levorphanol (9220) | II |
| Meperidine (9230) | II |
| Methadone (9250) | II |
| Methadone intermediate (9254) | II |
| Metopon (9260) | II |
| Dextropropoxyphene, bulk | |
| (non-dosage forms) (9273) | II |
| Morphine (9300) | II |
| Oripavine (9330) | II |
| Thebaine (9333) | II |

Drug Schedule

| Opium tincture (9630) | II |
|------------------------|----|
| Opium, powdered (9639) | II |
| Oxymorphone (9652) | II |
| Noroxymorphone (9668) | II |
| Alfentanil (9737) | II |
| Remifentanil (9739) | II |
| Sufentanil (9740) | II |
| Fentanyl (9801) | II |

The firm plans to manufacture the listed controlled substances for internal use and for sale to other companies.

Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR § 1301.33(a).

Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive,

Springfield, Virginia 22152; and must be filed no later than [insert date 60 days from date of publication].

Joseph T. Rannazzisi
Deputy Assistant Administrator
Office of Diversion Control
Drug Enforcement Administration

DATED: January 23, 2012

[FR Doc. 2012-1975 Filed 01/30/2012 at 8:45 am; Publication

Date: 01/31/2012]